Literature DB >> 4046704

The topical use of 5-fluorouracil in the ear in the management of cholesteatoma and excessive mucous secretion.

M F Smith.   

Abstract

5-Fluorouracil was introduced in the early 1960s as a topical chemotherapeutic agent and has become increasingly accepted because of its efficacy, economy, and relative absence of side effects in treating many pre-cancerous conditions, certain benign and malignant tumors, and dermatoses. This paper addresses the use of topical 5-fluorouracil in the management of cholesteatoma and unwanted mucus-secreting cells. A retrospective study has suggested a very impressive efficacy of topical 5-fluorouracil in the management of cholesteatoma and, to a lesser degree, control of hyper-mucus-secreting cells at locations in the middle ear and mastoid. The use of topical 5-fluorouracil in the management of hyperkeratosis, cholesteatoma in the middle ear and mastoid, and in the external canal has been almost 100% effective with very few side effects. In the management of hyper-mucous-secreting cells, 5-fluorouracil has a success rate of approximately 50%.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4046704     DOI: 10.1288/00005537-198510000-00010

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  3 in total

1.  Middle ear mucocele: an unusual complication of the tranlabyrinthine approach to acoustic neuroma.

Authors:  P Farris; K Brown; F Vuitch; W L Meyerhoff
Journal:  Skull Base Surg       Date:  1997

2.  Topical application of 5-fluorouracil on attic cholesteatoma results in downregulation of keratinocyte growth factor and reduction of proliferative activity.

Authors:  Tomomi Yamamoto-Fukuda; Mariko Terakado; Yoshitaka Hishikawa; Takehiko Koji; Haruo Takahashi
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-02-02       Impact factor: 2.503

3.  Inhibitory effect of mesna and 5-fluorouracil on propylene glycol-induced cholesteatoma in rats.

Authors:  Numan Kokten; Ozan Tuysuz; Tulay Zenginkinet; Fatih Mehmet Hanege; Mahmut Tayyar Kalcioglu
Journal:  Acta Otorhinolaryngol Ital       Date:  2021-10       Impact factor: 2.124

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.